DaVita Shares Surge to All-Time High After Strong Q1 2026 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy DVA?
Source: seekingalpha
- Strong Financial Performance: DaVita reported $3.5 billion in revenue for Q1 2026, reflecting approximately 6% year-over-year growth and exceeding market expectations by $60 million, indicating robust demand in the U.S. dialysis market.
- Stable Treatment Volume Growth: The company recorded over 7 million dialysis treatments in the U.S., with daily treatment volumes steady at 91,650, demonstrating its sustained service capacity and market share enhancement.
- Improved Profitability: Adjusted earnings per share reached $2.87, marking a ~44% year-over-year increase and surpassing Wall Street forecasts by $0.54, reflecting effective strategies in cost control and revenue growth.
- Optimistic Outlook: DaVita raised its adjusted EPS forecast for 2026 to between $14.10 and $15.20, up from the previous range of $13.60 to $15.00, showcasing the company's confidence in future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to fall
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 198.650
Low
144.00
Averages
162.50
High
190.00
Current: 198.650
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Greg Abel's First Shareholder Meeting as CEO Receives Mixed Reviews
- Attendance at Shareholder Meeting: Greg Abel's first annual meeting as CEO saw attendance at just over half capacity, indicating a significant drop in draw compared to the Buffett and Munger era, although it still surpassed typical corporate annual meetings.
- Capital Allocation Concerns: Abel's failure to provide clear guidance on the future of Berkshire's equity portfolio and substantial cash reserves has heightened investor concerns regarding the company's capital allocation strategy, potentially impacting market confidence in Berkshire.
- Lackluster Buyback Performance: Despite announcing a resumption of stock buybacks, Berkshire repurchased only $234 million in shares during Q1, falling short of market expectations and possibly undermining investor trust in the company's buyback strategy.
- New CFO Compensation: The new CFO, Charles Chang, will receive an annual salary of $8 million, a significant increase compared to the previous CFO Marc Hamburg's total compensation of $4.3 million, raising potential shareholder concerns about the reasonableness of executive pay.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
DaVita to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will engage in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM EDT, highlighting the company's commitment to investor relations.
- Global Patient Reach: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S. and 596 in 14 other countries, showcasing its extensive global footprint in kidney care.
- Leadership in Clinical Quality: With over 25 years of experience, DaVita has led the kidney care sector by reducing hospitalizations, improving mortality rates, and enhancing health access, thereby pushing the kidney care community to adopt higher quality standards for patient care.
- Comprehensive Care Model: DaVita is committed to supporting patients at every stage of their kidney health journey, providing care in homes, dialysis centers, hospitals, and skilled nursing facilities, ensuring high-quality care across various settings.
See More
DaVita CFO to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM, highlighting the company's commitment to investor engagement.
- Global Patient Service: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S., showcasing its extensive influence in the global kidney care sector.
- Innovative Care Models: As a comprehensive kidney care provider, DaVita has focused on clinical quality and innovation for over 25 years, aiming to enhance patient quality of life and drive the kidney care community towards higher care standards.
- Reduced Hospitalization Rates: DaVita has successfully lowered hospitalization rates and improved patient mortality through enhanced medical services, providing support at all stages of care, thereby demonstrating its leadership in kidney health management.
See More
Health Care Stocks Rise as NYSE Health Care Index Increases
- Strong Performance in Health Care Stocks: Late Wednesday afternoon, health care stocks were broadly higher, reflecting market optimism about the health sector, likely driven by investor expectations for future growth in healthcare demand.
- NYSE Health Care Index Increase: The rise in the NYSE Health Care Index indicates increased investor confidence in the healthcare sector, which may attract more capital into the field, thereby enhancing overall market performance.
- Market Trend Analysis: The upward trend in the healthcare sector may be linked to recent policy changes and technological innovations, with investor positive reactions potentially further driving stock prices higher.
- Improved Investor Sentiment: As health care stocks rise, investor sentiment has improved, which may lead to increased capital inflow into healthcare stocks, further propelling industry growth and development.
See More
DaVita Shares Surge to All-Time High After Strong Q1 2026 Earnings Report
- Strong Financial Performance: DaVita reported $3.5 billion in revenue for Q1 2026, reflecting approximately 6% year-over-year growth and exceeding market expectations by $60 million, indicating robust demand in the U.S. dialysis market.
- Stable Treatment Volume Growth: The company recorded over 7 million dialysis treatments in the U.S., with daily treatment volumes steady at 91,650, demonstrating its sustained service capacity and market share enhancement.
- Improved Profitability: Adjusted earnings per share reached $2.87, marking a ~44% year-over-year increase and surpassing Wall Street forecasts by $0.54, reflecting effective strategies in cost control and revenue growth.
- Optimistic Outlook: DaVita raised its adjusted EPS forecast for 2026 to between $14.10 and $15.20, up from the previous range of $13.60 to $15.00, showcasing the company's confidence in future performance.
See More
Greg Abel's First Shareholder Meeting as CEO Receives Mixed Reviews
- Attendance at Shareholder Meeting: Greg Abel's first annual meeting as CEO saw attendance at just over half capacity, indicating a significant drop in draw compared to the Buffett and Munger era, although it still surpassed typical corporate annual meetings.
- Capital Allocation Concerns: Abel's failure to provide clear guidance on the future of Berkshire's equity portfolio and substantial cash reserves has heightened investor concerns regarding the company's capital allocation strategy, potentially impacting market confidence in Berkshire.
- Lackluster Buyback Performance: Despite announcing a resumption of stock buybacks, Berkshire repurchased only $234 million in shares during Q1, falling short of market expectations and possibly undermining investor trust in the company's buyback strategy.
- New CFO Compensation: The new CFO, Charles Chang, will receive an annual salary of $8 million, a significant increase compared to the previous CFO Marc Hamburg's total compensation of $4.3 million, raising potential shareholder concerns about the reasonableness of executive pay.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
DaVita to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will engage in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM EDT, highlighting the company's commitment to investor relations.
- Global Patient Reach: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S. and 596 in 14 other countries, showcasing its extensive global footprint in kidney care.
- Leadership in Clinical Quality: With over 25 years of experience, DaVita has led the kidney care sector by reducing hospitalizations, improving mortality rates, and enhancing health access, thereby pushing the kidney care community to adopt higher quality standards for patient care.
- Comprehensive Care Model: DaVita is committed to supporting patients at every stage of their kidney health journey, providing care in homes, dialysis centers, hospitals, and skilled nursing facilities, ensuring high-quality care across various settings.
See More
DaVita CFO to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM, highlighting the company's commitment to investor engagement.
- Global Patient Service: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S., showcasing its extensive influence in the global kidney care sector.
- Innovative Care Models: As a comprehensive kidney care provider, DaVita has focused on clinical quality and innovation for over 25 years, aiming to enhance patient quality of life and drive the kidney care community towards higher care standards.
- Reduced Hospitalization Rates: DaVita has successfully lowered hospitalization rates and improved patient mortality through enhanced medical services, providing support at all stages of care, thereby demonstrating its leadership in kidney health management.
See More
Health Care Stocks Rise as NYSE Health Care Index Increases
- Strong Performance in Health Care Stocks: Late Wednesday afternoon, health care stocks were broadly higher, reflecting market optimism about the health sector, likely driven by investor expectations for future growth in healthcare demand.
- NYSE Health Care Index Increase: The rise in the NYSE Health Care Index indicates increased investor confidence in the healthcare sector, which may attract more capital into the field, thereby enhancing overall market performance.
- Market Trend Analysis: The upward trend in the healthcare sector may be linked to recent policy changes and technological innovations, with investor positive reactions potentially further driving stock prices higher.
- Improved Investor Sentiment: As health care stocks rise, investor sentiment has improved, which may lead to increased capital inflow into healthcare stocks, further propelling industry growth and development.
See More
DaVita Shares Surge to All-Time High After Strong Q1 2026 Earnings Report
- Strong Financial Performance: DaVita reported $3.5 billion in revenue for Q1 2026, reflecting approximately 6% year-over-year growth and exceeding market expectations by $60 million, indicating robust demand in the U.S. dialysis market.
- Stable Treatment Volume Growth: The company recorded over 7 million dialysis treatments in the U.S., with daily treatment volumes steady at 91,650, demonstrating its sustained service capacity and market share enhancement.
- Improved Profitability: Adjusted earnings per share reached $2.87, marking a ~44% year-over-year increase and surpassing Wall Street forecasts by $0.54, reflecting effective strategies in cost control and revenue growth.
- Optimistic Outlook: DaVita raised its adjusted EPS forecast for 2026 to between $14.10 and $15.20, up from the previous range of $13.60 to $15.00, showcasing the company's confidence in future performance.
See More
